We came across a bullish thesis on Achieve Life Sciences, Inc. on Hunterbrook’s Substack. In this article, we will summarize the bulls’ thesis on ACHV. Achieve Life Sciences, Inc.'s share was trading at $4.18 as of January 30th.
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. ACHV is approaching a pivotal inflection point as it awaits FDA approval for cytisinicline, a plant-derived, non-nicotine therapy designed to treat smoking...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.